Clofibrate is the treatment of choice in exudative diabetic retinopathy. With a low dose the exudates disappear, on the condition to carry on the treatment during several years. 1 or 2 capsules a day (500 or 1 000 mg/day) is enough. At this dose the tolerance is very good, allowing a regular and non-stop treatment.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Barriers to Yearly Diabetic Retinopathy Screening Attendance: A Retrospective Clinical Audit.
Cureus
December 2024
Ophthalmology, Calderdale Royal Hospital, Halifax, GBR.
Diabetic retinopathy is the most common sight-threatening complication of diabetes, necessitating regular monitoring of progression via diabetic eye screening (DES). The National Institute for Health and Care Excellence (NICE) recommends DES annually for diabetic patients aged 12 years and older. This retrospective clinical audit assessed the reasons behind non-attendance and evaluated the adherence to guidelines set by NICE in a general practice with approximately 9000 patients.
View Article and Find Full Text PDFDiabetic Retinopathy Disease Burden in Patients With Lower Household Incomes vs Higher Household Incomes.
J Vitreoretin Dis
January 2025
Department of Ophthalmology, Duke University School of Medicine, Durham, NC, USA.
To assess the differences in measures of diabetic retinopathy (DR) disease burden between patients in high-income vs low-income ZIP codes when presenting to retina specialists. This retrospective cohort study comprised patients who presented to a retina specialist at Duke Eye Center between 2014 and 2023 for the management of DR. The quartile of patients with the highest income was compared with the quartile with the lowest income.
View Article and Find Full Text PDFInhibition of Vascular Endothelial Growth Factor Reduces Photoreceptor Death in Retinal Neovascular Disease via Neurotrophic Modulation in Müller Glia.
Mol Neurobiol
January 2025
Department of Ophthalmology, Ruijin Hospital, Affiliated Shanghai Jiaotong University School of Medicine, 197 Ruijin Er Road, Shanghai, 200025, China.
VEGF is not only the most potent angiogenic factor, but also an important neurotrophic factor. In this study, vitreous expression of six neurotrophic factors were examined in proliferative diabetic retinopathy (PDR) patients with prior anti-VEGF therapy (n = 48) or without anti-VEGF treatment (n = 41) via ELISA. Potential source, variation and impact of these factors were further investigated in a mouse model of oxygen-induced retinopathy (OIR), as well as primary Müller cells and 661W photoreceptor cell line under hypoxic condition.
View Article and Find Full Text PDFDeep learning model for automatic detection of different types of microaneurysms in diabetic retinopathy.
Eye (Lond)
January 2025
Department of Surgical Sciences, University of Turin, Turin, Italy.
Purpose: This study aims to develop a deep-learning-based software capable of detecting and differentiating microaneurysms (MAs) as hyporeflective or hyperreflective on structural optical coherence tomography (OCT) images in patients with non-proliferative diabetic retinopathy (NPDR).
Methods: A retrospective cohort of 249 patients (498 eyes) diagnosed with NPDR was analysed. Structural OCT scans were obtained using the Heidelberg Spectralis HRA + OCT device.
Deep learning generalization for diabetic retinopathy staging from fundus images.
Physiol Meas
January 2025
Biomedical Engineering Faculty, Technion Israel Institute of Technology, Technion city, Haifa, Haifa, 32000, ISRAEL.
Diabetic retinopathy (DR) is a serious diabetes complication that can lead to vision loss, making timely identification crucial. Existing data-driven algorithms for DR staging from digital fundus images (DFIs) often struggle with generalization due to distribution shifts between training and target domains. To address this, DRStageNet, a deep learning model, was developed using six public and independent datasets with 91,984 DFIs from diverse demographics.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!